ArticleJournal of neuro-oncology2026
Post-operative day one discharge following craniotomy for tumour resection.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePost-operative admission following craniotomy for tumour resection (CTR) remains standard practice. To improve efficiency, optimise patient flow, and reduce length of stay (LOS), a post-operative day one (POD1) discharge pathway was implemented. This study evaluated the feasibility of POD1 discharge and identified factors associated with delayed discharge and 30-day unplanned readmission.
methodsA retrospective analysis of 263 consecutive patients undergoing CTR between November 2022 and December 2023 was performed. Baseline demographic, clinical, tumour-related, operative, and post-operative variables were collected. The primary outcome was POD1 discharge. Secondary outcomes included 30-day unplanned readmission and factors associated with discharge and readmission. Univariable logistic regression and Fisher's exact test were used.
resultsPOD1 discharge was achieved in 146 patients (55.5%). The overall 30-day unplanned readmission rate was 8.0%, including 7.5% among patients discharged on POD1. Mean cumulative 30-day hospital days were 1.0 days among patients discharged on POD1 compared with 7.0 days among patients requiring prolonged admission. POD1 discharge was not associated with increased odds of readmission (OR 0.87, 95% CI 0.35-2.17, p = 0.760). Diabetes mellitus (OR 0.41, 95% CI 0.17-0.96, p = 0.044), post-operative adverse events (OR 0.18, 95% CI 0.06-0.47, p = 0.001), and post-operative neurological deficits (OR 0.05, 95% CI 0.01-0.17, p < 0.001) were associated with reduced odds of POD1 discharge. Eloquent tumour location was associated with increased odds of readmission (OR 3.35, 95% CI 1.36-8.78, p = 0.010).
conclusionPOD1 discharge following CTR was feasible in more than half of patients and was not associated with increased 30-day readmission. These findings support structured POD1 discharge pathways in appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.